The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

• Status: Unknown status
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Anzhen Hospital
• Treatments: Calcium heparin; Dalteparin; Enoxaparin; Enoxaparin sodium; Heparin; Heparin, Low-Molecular-Weight; Platelet Aggregation Inhibitors; Ticagrelor; Tinzaparin

Criteria

Inclusion Criteria:

1. Age ≥18 years old and ≤75 years ;

2. unstable angina, non-ST segment elevation acute myocardial infarction, old myocardial infarction, or confirm the presence of myocardial ischemia;

3. voluntary participation in clinical trials, and informed consent;

Exclusion Criteria:

1. acute ST segment elevation myocardial infarction, stable angina pectoris;

2. aspirin allergy or resistance;

3. consolidated stroke, chronic obstructive pulmonary disease and other ticagrelor contraindications;

4. patients have coagulopathy;

5. can not be continued for one year with aspirin and treatment of dual antiplatelet ticagrelor;

6. can not complete revascularization;

7. NYHA ≥Ⅲ level or left ventricular ejection fraction <40%;

8. severe liver and kidney dysfunction (ALT and AST were more than three times the upper limit of normal, creatinine clearance less than 30ml / min-1.1.72m-2);